Tag Archives: AChEIs

Pharmacological Treatments for Alzheimer’s Disease in Primary Care / Management of Cognitive Symptoms (DTB / Nursing Times)

Summary A Drug and Therapeutics Bulletin (DTB) article reviews the evidence concerning drugs prescribed for cognitive symptoms in Alzheimer’s Disease and discusses some issues in their prescription. Donepezil, galantamine and rivastigmine are licensed for mild to moderate Alzheimer’s Disease in … Continue reading

Posted in Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Management of Condition, Models of Dementia Care, NICE Guidelines, Pharmacological Treatments, Practical Advice, Quick Insights, UK | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease (Health Technology Assessment)

[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 11, June 2012]. Summary The purpose of this Health Technology Assessment was to review and update guidance to the NHS in England and Wales … Continue reading

Posted in Acute Hospitals, Community Care, For Doctors (mostly), For Researchers (mostly), Management of Condition, National, NHS, NIHR, Pharmacological Treatments, Proposed for Next Newsletter, Systematic Reviews, UK | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Who Benefits Most From Cognitive Stimulation Therapy (CST)? (University College London)

[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 11, June 2012]. Summary The study investigated the factors which predict who is likely to benefit from Cognitive Stimulation Therapy (CST). Two hundred and seventy-two … Continue reading

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Management of Condition, Non-Pharmacological Treatments, Universal Interest | Tagged , , , , , , , , , , , | Leave a comment